Treating poor nasal breathers simply and non-surgically
This article was originally published in Start Up
Faced with the large unmet clinical need of people with chronic nasal obstruction, an ENT physician formed Spirox to develop a non-surgical implant to restore the nasal valve. The ultimate goal is to develop a 15-minute procedure that ENTs can perform in their office to help patients breathe better.
You may also be interested in...
Competition breeds innovation, and the ear, nose, and throat (ENT) market, once a fairly quiet arena, is now positioned to host some spirited activity that should lead to new technologies. Several large device manufacturers have recently moved into the ENT space, and the sinus treatment segment of the market has become one of the focal points for emerging competitors, as companies work toward less-invasive treatment options.
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.